Company intelligence / Profile preview

NeuroNova

Stockholm, Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

NeuroNova developed sNN0031 (PDGF-BB) for Parkinson's disease (completed Phase I/II with preliminary positive effects on biochemical markers and safety) and sNN0029 (VEGF) for ALS (early clinical activity; placebo-controlled trials planned, but development moved to Newron Pharmaceuticals after the acquisition).

Therapeutic areas: Neurology
Modalities: ProteinBiologic
Industry: Biotech

Partnerships

Karolinska InstitutetInvestor ABHealthCap

Beyond the preview

Go deeper on NeuroNova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroNova.

Explore the full profile